Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.
 
Second quarter 2023 for the group
Income amounted to TSEK 0 (0).
Loss before and tax totalled TSEK 18,401 (loss: 18,942).
Loss per share* was SEK 0.06 (loss: 0.21).

First half year 2023 for the group
Income amounted to TSEK 0 (0).
Loss before and tax totalled TSEK 34,244 (loss: 35,326).
Loss per share* was SEK 0,11 (loss: 0,40)
 
Second quarter 2023 for the parent company
Income amounted to TSEK 0 (0).
Loss before and after tax totalled TSEK 11,151 (loss: 11,547).
Loss per share* was SEK 0.04 (loss: 0.13).
 
First half year 2023 for the parent company
Income amounted to TSEK 0 (0).
Loss before and after tax totalled TSEK 21,553 (loss: 22,589).
Loss per share* was SEK 0,07 (loss: 0,26).
At June 30, 2023, the equity/assets ratio** was 17 % (-99).
 
Significant events in the second quarter of 2023
» Xintela has started last dose level of XSTEM in knee osteoarthritis clinical study. (April 13, 2023)
» Xintela is carrying out a Rights issue of units of approximately SEK 123 million. (May 24, 2023)
» Xintela's clinical study with XSTEM for knee osteoarthritis makes good progress. (June 1, 2023)
» Xintela publishes positive preclinical results from XSTEM treatment of ARDS. (June 9, 2023)
» Xintela completes XSTEM dosing at third and final dose level in knee osteoarthritis clinical study. (June 22, 2023)
 
Significant events after the end of the period
» Xintela publishes the outcome of the rights issue. (July 4, 2023)
» Xintela gets product patent in USA for chondrocyte-based products. (August 15, 2023)

The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports.